GRAMD2B

Across TCGA pan-cancer cohorts, GRAMD2B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRAMD2B data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GRAMD2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GRAMD2B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where GRAMD2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.875	.012	15	view →
HNSC	DFS	Tertile	III,IV	0.832	0.318	.004	15	view →
UCEC	DFS	Median	All	0.965	0.835	.008	12	view →
LUAD	DFS	Quartile	All	0.534	0.823	.013	6	view →
GBM	DFS	Quartile	All	0.166	0.434	.019	5	view →
PDAC	DFS	Quartile	All	0.636	0.860	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRAMD2B–CCRCC (DFS)

Open the CCRCC breakdown →